1. Home
  2. ETON vs TLSA Comparison

ETON vs TLSA Comparison

Compare ETON & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$18.93

Market Cap

411.9M

Sector

Health Care

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.22

Market Cap

166.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
TLSA
Founded
2017
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
411.9M
166.7M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
ETON
TLSA
Price
$18.93
$1.22
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$31.00
N/A
AVG Volume (30 Days)
291.1K
93.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,011,000.00
N/A
Revenue This Year
$107.23
N/A
Revenue Next Year
$29.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.29
N/A
52 Week Low
$11.09
$0.73
52 Week High
$23.00
$2.60

Technical Indicators

Market Signals
Indicator
ETON
TLSA
Relative Strength Index (RSI) 64.96 35.66
Support Level $16.04 N/A
Resistance Level $20.01 $1.56
Average True Range (ATR) 1.08 0.10
MACD 0.10 -0.01
Stochastic Oscillator 70.56 9.46

Price Performance

Historical Comparison
ETON
TLSA

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: